Comparison of angiographic change in side-branch ostium after drug-coated balloon vs. drug-eluting stent vs. medication for the treatment of de novo coronary bifurcation lesions

Objectives Data on side-branch (SB) ostial effect after drug-coated balloon (DCB) treatment in the context of de novo coronary bifurcation lesions are limited. We aimed to investigate the angiographic outcomes of SB ostium after DCB treatment compared with drug-eluting stents (DESs) implantation in the main vessel (MV) or optimal medical therapy (OMT) for the treatment of de novo coronary bifurcation lesions. Methods Serial angiographic changes in the SB ostium were compared between DCB, DES, and medication alone for MV treatment. Δ value was calculated by subtracting the follow-up value from the pre-procedure value. Results A total of 132 bifurcation lesions were included for analysis (44 lesions in DCB group; 38 lesions in DES group; 50 lesions in OMT group). The minimal lumen diameter (MLD) of SB ostium showed an increase at follow-up in the DCB group, whereas a decrease was observed in both the DES and OMT groups (ΔMLD: −0.16 ± 0.45 mm for DCB group vs. 0.50 ± 0.52 mm for DES group vs. 0.08 ± 0.38 mm for OMT group, p < 0.001). The diameter stenosis (DS) of SB ostium showed a marked decrease at follow-up in the DCB group, in contrast to an increase observed in both the DES and OMT groups (ΔDS: 8.01 ± 18.96% for DCB group vs. −18.68 ± 18.60% for DES group vs. −2.05 ± 14.58% for OMT group, p < 0.001). Conclusions In de novo coronary bifurcation lesions, DCB treatment on the MV demonstrated favorable angiographic outcomes in the SB ostium at 6–9 month follow-up compared to DES implantation or OMT. Supplementary Information The online version contains supplementary material available at 10.1186/s40001-024-01877-6.


Introduction
In the current era of percutaneous coronary intervention (PCI), bifurcation lesion remains a challenging lesion subset which is encountered in up to 20% of all PCI and an independent risk factor for worse clinical outcomes than non-bifurcation lesions [1].Although previous studies have showed the procedural success and improving efficacy of emerging techniques or devices, most of the evidence is limited to drug-eluting stent (DES) and one of the significant complications for bifurcation PCI is side-branch (SB) occlusion and the most site of in-stent restenosis (ISR) of bifurcation is SB ostium after stenting [2,3].Stenting of bifurcation lesions presents certain drawbacks, including the potential for distal vessel overstretching and vessel straightening, both of which can result in a carina or plaque shift into the SB [4].Despite the appearance of improved flow conditions in the straightened main vessel (MV), the final outcome is actually a compromised situation influenced by the neighboring SB [5].
Because drug-coated balloon (DCB) treatment leaves nothing of lesions behind, it reduces the risk of stentrelated adverse biological responses that contribute to restenosis and thrombosis and facilitates favorable natural healing of the vessel [6][7][8][9].Besides delivering an antiproliferative drug, DCB also contributes to mechanical expansion, resulting in positive vessel remodeling characterized by late lumen enlargement, plaque reduction, and plaque stabilization [10][11][12].A previous study demonstrated that DCB treatment of de novo lesions in the MV did not compromise the SB ostium [4].Instead, it resulted in an increase in the lumen area of the SB ostium after 9-month follow-up.The SB ostial lumen area increased 52.1% (IQR of −0.7% to 77.3%) between postprocedure and 9-month follow-up and 76.1% (IQR 18.2 -86.6%) between pre-procedure and 9-month follow-up [4].Nevertheless, there have been no comparative studies between DCB treatment for SB ostium in de novo bifurcation lesions and other treatment modalities like DES implantation or optimal medical therapy (OMT) only without interventional treatment.
Therefore, the aim of this study was to evaluate the effects on SB ostium following DCB treatment compared with DES implantation in the MV or OMT only for de novo coronary bifurcation lesions.

Patient population
Among the patients treated with DCB for de novo coronary artery disease (CAD) included in the DCB registry (Impact of Drug-coated Balloon Treatment in de Novo Coronary Lesion; NCT04619277), a total of 132 patients with de novo bifurcation lesions were retrospectively enrolled from two teaching hospitals in South Korea (Ulsan University Hospital, Ulsan Medical Center).These patients underwent either DCB treatment, DES implantation in the MV, or OMT without interventional treatment.Specifically, when the physician concluded that PCI was not necessary for the bifurcation lesion, OMT was exclusively carried out.The inclusion criteria were bifurcation lesions with a main vessel (MV) diameter of ≥ 3.0 mm and side branch (SB) diameter of ≥ 2.0 mm by visual estimation; however, cases with greater than 50% significant stenosis in the SB ostium were excluded.Exclusion criteria included lesions that require an upfront 2-stent approach or provisional stenting, heavily calcified or thrombotic lesions, chronic total occlusion lesion, left ventricular ejection fraction < 30%, cardiogenic shock, life expectancy < 1 year, and known chronic kidney disease (creatinine > 2 mg/dL).The study protocol received approval from the institutional review board of each participating center, and all patients provided written informed consent at the time of enrollment.

Procedure
For patients with bifurcation lesions, balloon angioplasty was performed to assess the feasibility of DCB treatment in the MV for PCI.The DCB treatment followed the recommendations of international and Asia-Pacific consensus guidelines for DCB treatment [13][14][15].It was mandatory to perform pre-dilatation using a plain balloon with a recommended balloon-to-vessel ratio of 0.8-1.0.After successful pre-dilatation, stenting was delayed for all types of dissections (A to E) if thrombolysis in myocardial infarction (TIMI) grade 3 flow was attained.In cases of flow-limiting dissection after pre-dilatation (TIMI flow grade < 3) or > 30% visual residual stenosis, PCI with stent implantation was recommended.In cases where flow was reduced due to compromise of the SB after the procedure, provisional stenting at SB was performed and was excluded from this study.Therefore, in this study, all patients undergoing DES implantation were managed using the simple crossover 1-stent approach in the MV.All DCBs used were coated with 3.0 μg/mm 2 paclitaxel combined with iopromide (SeQuent Please © by B. Braun, Germany) as a drug carrier.

Quantitative coronary angiography (QCA) data
Coronary angiography was performed before and after PCI, during routine 6-9 month angiographic follow-up, and in cases where PCI was deemed necessary due to the presence of new lesions.Quantitative analysis of angiographic data was analyzed offline by a single independent expert in blinded core lab (Cardiovascular Research Foundation in Dong-A University Hospital) using the validated software (Medis Suite XA, Medis, Leiden, The Netherlands).The MV and the SB were assessed separately.To evaluate changes in the SB ostium and the MV, bifurcation lesions were divided into five segments for quantitative coronary angiographic analysis: the SB ostium, proximal MV, distal MV, upper rim of confluence in MV, and lower rim of confluence in MV, as illustrated in Fig. 1.In addition, Δ value was calculated by subtracting the follow-up value from the pre-procedural value.
• Upper rim of confluence in MV: first frame proximally to the take-off of the SB ostium.
• Lower rim of confluence in MV: first frame distally to the take-off of the SB ostium.
• ΔUpper rim diameter at confluence = (Upper rim diameter of confluence at pre-procedure) -(Upper rim diameter of confluence at follow-up) • ΔLower rim diameter of confluence = (Lower rim diameter of confluence at pre-procedure) -(Lower rim diameter of confluence at follow-up)

Clinical follow-up
All 132 patients underwent a clinical follow-up following the index procedure via telephone interviews and outpatient clinic visits.The major adverse events at 1 year were cardiac death, myocardial infarction (MI), stroke, probable or definite device or stent thrombosis, target vessel revascularization (TVR), and major bleeding.Cardiac death was defined as any death that was not clearly of extracardiac origin, including MI, according to previously published guidelines [16].Additionally, probable or definite device or stent thrombosis was defined according to the definition by the Academic Research Consortium [17], and major bleeding was defined as Bleeding Academic Research Consortium type 3 to 5 bleeding [18].

Statistical analysis
For continuous variables, intergroup differences were evaluated using the unpaired t test or Mann-Whitney rank test.Analysis of variance (ANOVA) test was used to compare differences of means among three groups.Data are expressed as mean ± standard deviation.For discrete variables, intergroup differences are expressed as count and percentage, and were analyzed with the χ2 or Fisher's exact test.All p values were two-sided, and values of < 0.05 were considered statistically significant.R version 4.1.2(R Foundation for Statistical Computing, Vienna, Austria) was used to perform the statistical analysis.

Results
Among a total of 132 patients with bifurcation lesions, 44 patients (33.3%) composed the DCB group, 38 patients (28.8%) composed the DES group, and 50 patients (37.9%) were received medical therapy alone (OMT group).The baseline clinical and procedural characteristics of the patients are presented in Table 1.Among the three groups, the DCB group exhibited a significantly higher incidence of dyslipidemia compared to the other groups (61.4% for DCB group vs. 31.6%for DES group vs. 40.0%for OMT group; p = 0.018).Furthermore, the DCB and DES groups had the highest proportion of patients with unstable angina, whereas the OMT group had mainly stable angina (unstable angina: 56.8% for DCB group vs. 63.2% for DES group vs. 38.0%for OMT group; stable angina: 34.1% for DCB group vs. 21.0%for DES group vs. 44.0%for OMT group, p = 0.021).
The QCA data are showed in Table 2 and Supplementary Table 1.The MLD of SB ostium showed an increase at 6-9 month follow-up in the DCB group, whereas a decrease was observed in both the DES and OMT groups (ΔMLD: −0.16 ± 0.45 mm for DCB group vs. 0.50 ± 0.52 mm for DES group vs. 0.08 ± 0.38 mm for OMT group, p < 0.001) (Figs.2A and 3A and Central Illustration Fig. 3C).The DS of SB ostium showed a marked decrease at 6-9 month follow-up in the DCB group, in contrast to an increase observed in both the DES and OMT groups (ΔDS: 8.0 ± 19.0% for DCB group vs. −18.7 ± 18.6% for DES group vs. −2.1 ± 14.6% for OMT group, p < 0.001) (Fig, 3B, C).The MLD in the MV showed an increase at 6-9 month follow-up in both the DCB and DES groups, while a decrease was observed in the OMT group (ΔMLD: −1.11 ± 0.58 mm for DCB group vs. −1.18± 0.50 mm for DES group vs. 0.03 ± 0.27 mm for OMT group, p < 0.001) (Fig. 2B and Supplementary Fig. 1A).The DS in the MV showed a marked decrease at 6-9 month follow-up in both the DCB and DES groups, contrasting with a smaller decrease observed in the OMT group (ΔDS: 38.5 ± 19.0% for DCB group vs. 35.7 ± 13.5% for DES group vs. 0.7 ± 8.6% for OMT group, p < 0.001) (Supplementary Fig. 1B).The upper and lower rim diameter of confluence in the MV also showed increases at 6-9 month follow-up in both the DCB and DES groups, while decreases were observed in the OMT group (Δupper rim: −0.76 ± 0.79 mm for DCB group vs. −0.68 ± 0.70 mm for DES group vs. 0.11 ± 0.30 mm for OMT group, p < 0.001; Δlower rim: −0.75 ± 0.66 mm for DCB group vs. −0.83± 0.69 mm for DES group vs. 0.01 ± 0.29 mm for OMT group, p < 0.001).The results obtained from the analysis of true bifurcation lesions in Supplementary Table 1 were consistent with those of all bifurcation lesions in Table 2.In true bifurcation lesions, compared to all bifurcation lesions, the pre-procedural MLD of the SB ostium was smaller and the DS was more severe.However, after DCB treatment, the absolute values of ΔMLD and ΔDS were actually greater after follow-up.
No additional bailout stenting, SB occlusion, or slow flow (TIMI < 3) occurred after DCB treatment.During

Discussion
This study provided that DCB treatment of MV alone on de novo coronary bifurcation lesions resulted in an increase in the SB ostial lumen diameter and a decrease in the SB ostial stenosis at 6-9 month follow-up, as compared to DES implantation or OMT therapy.
DES implantation in bifurcation lesions, as with any current stenting strategy, has an impact on the regional arterial geometry, thereby causing modifications to local flow conditions and damages to the SB ostium [19,20].Hahn et al. demonstrated that after DES implantation for bifurcation lesions, 8.4% of patients experienced SB occlusion, and those with SB occlusion had a higher incidence of cardiac death or MI compared to those without SB occlusion (aHR: 2.34; 95% CI 1.15 to 4.77; p = 0.02) [21].These stent-induced alterations of blood flow result in complex spatiotemporal modifications in wall shear stress, which subsequently enhance the thrombogenicity around the stent struts and alterations in the endothelial phenotype that facilitate the migration of inflammatory cells [22].If plaque burden within the bifurcation lesions is adequately reduced and the arterial geometry and blood flow are maintained without the inclusion of foreign materials like stent struts, it would represent an ideal bifurcation PCI.
DCB may offer several advantages over DES by ensuring immediate and homogeneous drug uptake by the vessel wall, without the potential for inflammatory reactions associated with stent struts or polymers, and maintaining the original anatomy of the bifurcation [23].To date, previous bifurcation studies for DCB treatment have primarily examined the results of using DCB sequentially on the MV and SB while stenting the MV [24][25][26][27].However, these studies have been limited in accurately assessing the direct impact on the SB ostium following DCB treatment in bifurcation lesions, primarily due to the presence of a stent in the MV.Almost exclusively, Her et al. demonstrated the benefits of avoiding carina shift and maintaining the natural distribution of blood flow through an increase in the SB ostium when applying a DCB-only approach to the MV [4].Nevertheless, it should be noted that the study was a single-arm trial and did not directly compare the approach with stenting.
This study is the first to demonstrate a difference in the serial angiographic change of SB ostium according to the treatment strategy on MV including DCB-only approach, DES implantation, or OMT alone.In this study, the comparison of the angiographic changes in the SB ostium from baseline to follow-up revealed that the SB ostium in the DCB group markedly increased, whereas in the DES and OMT groups tended to decrease.Therefore, these findings of this study provide direct evidence that the effect of DCB application on the MV in bifurcation lesions, which extends to the SB ostium, can be beneficial in reducing complications associated with the SB.
The specific finding by which DCB treatment leads to the enlargement of the SB ostium adjacent to the MV is not well-established, it may be explained that DCB does not have the restrictions of stents that inhibit vessel enlargement, potentially facilitating an increase in vessel diameter [28][29][30].When pre-dilatation creates a deep dissection that extends into the tunica media, the tunica media becomes exposed to the vessel lumen, which can result in vascular enlargement [31].Additionally, it may be a result of positive vessel remodeling caused by the localized drug delivery effects from DCB treatment [31,32].Despite the absence of a metal foreign body such as DES in the MV, the OMT group did not show any changes in the SB ostium.Conversely, the DCB group exhibited an enlarging effect on the SB ostium, suggesting a possible explanation.
Our study has several limitations that should be taken into account.First, it was an observational study conducted with a limited number of patients and lesions.Nonetheless, we made efforts to conduct a meticulous analysis by a single independent expert from a blinded core lab to overcome this limitation.Second, betweengroup bias appears to exist as the treatment strategy was determined by physicians.DES was implanted only in cases where DCB was deemed unacceptable following pre-dilatation.Additionally, due to the limited use of intravascular imaging during follow-up, precise assessments of vessel area or plaque area were not available.However, to report the changes in the SB ostium objectively based on real clinical practice, we utilized QCA according to the treatment strategy.Further validation studies are necessary to confirm the effect of plaque regression and vessel enlargement associated with DCB treatment on bifurcation lesion.It should also be revealed whether such results lead to improved outcomes.

Conclusions
DCB treatment on the MV in patients with de novo coronary bifurcation lesions showed better angiographic outcomes in the SB ostium compared to DES implantation or OMT alone after the 6-9 month follow-up.

Fig. 1
Fig. 1 Schematic diagram of quantitative coronary angiographic analysis for bifurcation lesions.MLD minimal lumen diameter, DS diameter stenosis, RD reference diameter

Fig. 2 Fig. 3
Fig. 2 Cumulative frequency distribution of angiographic change of (A) MLD in the SB ostium and (B) MLD in the MV between pre-procedure and 6-9 month follow-up according to treatment strategy.DCB drug-coated balloon, DES drug-eluting stent

Table 1
Baseline clinical and procedural characteristics of the patientsValues are presented as the mean ± SD or n (%) DCB drug-coated balloon, DES drug-eluting stent, LV left ventricular, CAD coronary artery disease, NSTEMI non-ST segment elevation myocardial infarction, STEMI ST-segment elevation myocardial infarction, LM left main, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery

Table 2
Quantitative coronary angiography measurementsValues are presented as the mean ± SD DCB drug-coated balloon, DES drug-eluting stent, MLD minimal lumen diameter, RD reference diameter, DS diameter stenosis